Analysts Set $175.00 Price Target for Mesa Laboratories, Inc. (MLAB)

Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) have been given an average broker rating score of 1.00 (Strong Buy) from the one brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy recommendation.

Brokers have set a twelve-month consensus price objective of $175.00 for the company and are predicting that the company will post $2.06 earnings per share for the current quarter, according to Zacks. Zacks has also assigned Mesa Laboratories an industry rank of 187 out of 265 based on the ratings given to related companies.

How to Become a New Pot Stock Millionaire

A number of research firms have recently weighed in on MLAB. BidaskClub upgraded Mesa Laboratories from a “buy” rating to a “strong-buy” rating in a report on Saturday, April 7th. ValuEngine upgraded Mesa Laboratories from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research upgraded Mesa Laboratories from a “sell” rating to a “hold” rating in a report on Wednesday, February 28th. Finally, TheStreet cut Mesa Laboratories from a “b-” rating to a “c” rating in a report on Wednesday, February 7th.

NASDAQ:MLAB traded up $0.92 during trading hours on Friday, hitting $169.35. The company had a trading volume of 14,571 shares, compared to its average volume of 17,696. The company has a quick ratio of 1.64, a current ratio of 2.37 and a debt-to-equity ratio of 0.58. The stock has a market cap of $641.81, a P/E ratio of 72.19 and a beta of 0.51. Mesa Laboratories has a 1 year low of $122.35 and a 1 year high of $170.69.

Mesa Laboratories (NASDAQ:MLAB) last released its quarterly earnings results on Monday, February 5th. The medical instruments supplier reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.77). The business had revenue of $23.67 million for the quarter, compared to analysts’ expectations of $23.10 million. Mesa Laboratories had a positive return on equity of 9.20% and a negative net margin of 3.82%. equities analysts anticipate that Mesa Laboratories will post 5.66 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 15th. Stockholders of record on Thursday, May 31st will be issued a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.38%. The ex-dividend date of this dividend is Wednesday, May 30th. Mesa Laboratories’s dividend payout ratio is presently 15.17%.

In related news, Director Robert V. Dwyer sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $144.01, for a total transaction of $720,050.00. Following the completion of the transaction, the director now directly owns 68,521 shares in the company, valued at approximately $9,867,709.21. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John James Sullivan sold 4,000 shares of the firm’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $138.00, for a total value of $552,000.00. Following the transaction, the director now owns 72,248 shares of the company’s stock, valued at $9,970,224. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,000 shares of company stock valued at $1,668,860. Company insiders own 15.70% of the company’s stock.

A number of institutional investors have recently made changes to their positions in MLAB. SG Americas Securities LLC purchased a new position in Mesa Laboratories during the 3rd quarter valued at about $131,000. Wells Fargo & Company MN boosted its holdings in Mesa Laboratories by 31.4% during the 3rd quarter. Wells Fargo & Company MN now owns 4,371 shares of the medical instruments supplier’s stock valued at $653,000 after acquiring an additional 1,045 shares during the period. Schwab Charles Investment Management Inc. raised its position in Mesa Laboratories by 149.5% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 11,976 shares of the medical instruments supplier’s stock valued at $1,789,000 after purchasing an additional 7,176 shares in the last quarter. Allianz Asset Management GmbH raised its position in Mesa Laboratories by 4.1% in the 3rd quarter. Allianz Asset Management GmbH now owns 23,250 shares of the medical instruments supplier’s stock valued at $3,472,000 after purchasing an additional 916 shares in the last quarter. Finally, Susquehanna International Group LLP acquired a new stake in Mesa Laboratories in the 3rd quarter valued at about $1,030,000. Institutional investors own 72.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/04/18/analysts-set-175-00-price-target-for-mesa-laboratories-inc-mlab.html.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.

Get a free copy of the Zacks research report on Mesa Laboratories (MLAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply